Archive | Biopharmaceuticals

Todays’ Sell-Off Finally Hits Resilient Biotech Stocks

click Facebook Hype Effect-Sell MO Stocks? Many of the favorite momentum stocks are being hit with profit taking today including large cap biopharmaceutical stocks. With the NASDAQ down 0.8% at 2850,  we see a lot of countertrends like gold up $39.70 off recent lows to $1576 accompanied by a big rally in silver and other metal stocks […]

Continue Reading 0

Biotech Sector Avoids Nasty Correction and Hits New Highs

buy neurontin Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in mid-April compared to the S&P […]

Continue Reading 0

Rayno Life Science Update-Macro Rules, Risk Off

modafinil to buy Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare The market continues to be weak with the NASDAQ entering its 5th day of the sell-off  down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has fared better down only 1.92% over five days and still up 18% YTD […]

Continue Reading 0

Market Sell-Off Continues: Biotechs Follow NASDAQ Down 1.56%

The NASDAQ Biotechnology Index IBB ($122.30)  is off 1.5% today and more than 2% off its all time high of $126.65. The first clue to the current sell-off was a CNBC Fast Money Contributor to buy the ETF XBI ($79) earlier in the week at its top of $82. Earlier this week we urged investors […]

Continue Reading 0

Rayno Life Science Portfolio Update: ALR, GPRO, REGN

Consolidation Continues in Mid Cap DX Companies: Bull Market in Biotech Hits New Highs Our Life Science Tools and Diagnostics Portfolio had a nice hit today with GenProbe up 18.75% on the Agreement that it would be sold to Hologic (HOLX $18.82 down 11.2%) for $3.7B or $82.75/sh. This is a strategic deal that builds […]

Continue Reading 0

Biopharmaceuticals Resist Market Correction: M&A du jour Ardea (RDEA)

Biotech Outperforming Tech Lately: M&A Hit of the Day Ardea Biosciences The market continues its choppy trend with the QQQ‘s off  0.9% to $65 with some Internet high fliers like AMZN and NFLX taking a hit. But biotech recovered from earlier losses with the IBB down only 0.35% and surprisingly  Alexion and Regeneron recovered from […]

Continue Reading 0

Rayno Life Science Portfolio: CBST, GILD,HGSI, REGN SQNM

Biotech Rally Ignited By Clinical News and M&A Theme The biotech sector roared back today with major ETF’s IBB ($122) up 2.4% and XBI ($78.6) up 5.1 % driven primarily by Gilead (GILD $52.23) up 12 % and other large caps like Regeneron (REGN $127) up 2.5%. Gilead (GILD) was up on clinical results from their […]

Continue Reading 0

Risk Off: Profit Taking, Spain and Jobs Data//BIO Update April 11

Nice Recovery in biotech today with our mid-cap index up almost 1%. Without doing a lot of detailed analysis it looks like stocks that have major institutional sponsors are rallying. Smaller caps without significant volume are still lagging. Two high fliers : Vivus (VVUS $22.15) and Medivation (MDVN $75.24) regained some composure after a bashing […]

Continue Reading 0

Rayno Biopharma Portfolio Update: ALXN, BIIB, CBST,REGN, VPHM

We have updated our Rayno Biopharmaceuticals Portfolio with total returns from inception 3/9/09 to 3/30/12. Biggest winners are Alexion (ALXN) Biogen (BIIB) , Cubist (CBST), Regeneron (REGN) and Viropharma (VPHM)-all over 200%. Over the same period the IBB ETF was up 75%. Losers were Albany Molecular (AMRI) down 40% and Gilead (GILD) down 4%. The ten […]

Continue Reading 0

Rayno Life Science Portfolio: Alexion (ALXN), Response Genetics (RGDX)

Two Companies With Major Biotech Themes: Orphan Drugs (ALXN) and Targeted Cancer Therapy (RGDX) IBB ($122) Weak Down 1% – 52 Week High of $124 One of our Top Performers in the biopharmaceutical sector Alexion (ALXN $89) took a hit this week and down over 3% today on volume of 2.7M shares, on an article […]

Continue Reading 0